South Africa Mpox Cases Rise to 18
Analysis based on 20 articles · First reported Sep 18, 2026 · Last updated Sep 19, 2026
The outbreak is a localized public-health event with limited direct market consequences, though it could weigh modestly on South African tourism and healthcare sentiment if case counts keep accelerating. Pharmaceutical demand for mpox vaccines and Tecovirimat may tick up, but the limited quantities secured mean any revenue effect is small.
South Africa's Department of Health has raised a public vigilance alert after a rapid increase in laboratory-confirmed mpox cases. As of 17 September 2026, the country had recorded 18 confirmed cases and one probable case, with 15 confirmed cases in the South Africa — Western Cape, mostly in the South Africa — Cape Town, three in South Africa — Gauteng and one probable case in South Africa — KwaZulu-Natal. Thirteen of the cases were recorded between 13 August and 17 September 2026, which the department says suggests rapid local transmission. Patients range in age from 23 to 50, with a median age of 36.5, and 18 of the 19 confirmed and probable cases involve men. One recent case involves a person who travelled to Spain earlier in September and returned to South Africa on 14 September 2026; South African authorities are working with Spanish counterparts to verify that person's laboratory results. Department spokesperson Foster Mohale urged immediate and sustained public cooperation, early detection and continued surveillance, and warned that stigma and discrimination could discourage people from seeking care. The government, with support from the World Health Organization, has secured limited doses of the MVA-BN mpox vaccine and the antiviral treatment Tecovirimat, with authorities to decide how to deploy them to disrupt local transmission.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard